Kazakhstan boosts drug output 37% to 191 bln tenge under Tokayev directive
This digest was compiled by AI from multiple sources — links to the originals are below.
Kazakhstan's pharmaceutical output rose 37% over three years to 191 billion tenge, with first-half 2026 production reaching 126.6 billion tenge, up nearly 30% year-on-year. The government reported 209 pharmaceutical and medical product manufacturers operating in the country, with domestic products accounting for 40.3% of the market in physical terms as of August 2026. Eight major projects worth 391.3 billion tenge are underway to expand production of over 494 drug names.
Key Facts
- Kazakhstan's pharmaceutical production reached 191 billion tenge over the past three years, a 37% increase.
- In the first half of 2026, output of medicines and medical devices totaled 126.6 billion tenge, up nearly 30% year-on-year.
- As of August 2026, domestic products accounted for 40.3% of the pharmaceutical market in physical terms.
- Eight major pharmaceutical projects worth 391.3 billion tenge are being implemented to produce over 494 drug names.
- International companies AstraZeneca, Pfizer, and Roche are participating in localization and technology transfer projects in Kazakhstan.
Production Growth
Kazakhstan's pharmaceutical output rose 37% over three years to 191 billion tenge, according to government data. In the first half of 2026, production of medicines and medical devices reached 126.6 billion tenge, nearly 30% higher than the same period last year. The country hosts 209 pharmaceutical and medical product manufacturers, including 43 drug-producing enterprises. Domestic products accounted for 40.3% of the market in physical terms as of August 2026. Kazakhstani companies have registered 2,994 names of medicines and medical devices.
Investment and Localization
Investment in the pharmaceutical industry grew 56% in 2025 to $142.8 million, with an additional $7.1 million attracted in the first quarter of 2026. AstraZeneca, Pfizer, and Roche are involved in projects to localize production and transfer technologies to Kazakhstan. Eight major projects for construction and expansion of pharmaceutical facilities are being implemented at a total cost of 391.3 billion tenge. These projects will enable Kazakhstan to produce over 494 drug names for the first time, including treatments for oncological, cardiovascular, autoimmune, orphan, and infectious diseases, as well as diabetes.
Procurement and Standards
As of early 2026, 83 long-term contracts are in effect with 31 domestic manufacturers for the supply of 2,022 product names. Medicines are produced according to GMP standards. The long-term procurement mechanism provides manufacturers with predictable demand and allows advance planning of capacity utilization, production expansion, and new drug launches.
9 sources
Kazakhstan boosts drug output 37% to 191 bln tenge under Tokayev directive
